Quadrant Capital Group LLC Erasca, Inc. Transaction History

Quadrant Capital Group LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 08, 2024	SELL	$1.67 - $2.49 $6,616 - $9,865	-3,962 Reduced 56.97%	2,992 $6,000
Q3 2023 Nov 14, 2023	BUY	$1.97 - $2.91 $11,429 - $16,883	5,802 Added 503.65%	6,954 $13,000
Q2 2023 Aug 09, 2023	BUY	$2.57 - $3.3 $961 - $1,234	374 Added 48.07%	1,152 $3,000
Q1 2023 May 11, 2023	BUY	$2.74 - $4.44 $1,268 - $2,055	463 Added 146.98%	778 $2,000
Q4 2022 Feb 10, 2023	BUY	$3.89 - $8.57 $1,225 - $2,699	315 New	315 $1,000

141

229M

28.7K

117K

Ticker ERAS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 122,147,000
Market Cap $333M
Description
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...

Get notified when there are updates to the investment portfolio of Quadrant Capital Group LLC, based on Form 13F filings with the SEC.

Stay updated on Quadrant Capital Group LLC with notifications on news.